Molecular Biomarkers and Recent Liquid Biopsy Testing Progress: A Review of the Application of Biosensors for the Diagnosis of Gliomas

Wu, Yuanbin; Wang, Xuning; Zhang, Meng; Wu, Dongdong

doi:10.3390/molecules28155660

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article3

Book1

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Biosensors and disease diagnostics in medical field

Channi,

Sandhu,

Ghai

et al. 2025

Data Science in the Medical Field

View full text Add to dashboard Cite

Biosensors and disease diagnostics in medical field

Channi,

Sandhu,

Ghai

et al. 2025

Data Science in the Medical Field

View full text Add to dashboard Cite

Liquid biopsy in diagnosis of central nervous system tumors

Gavryushin,

Veselkov,

Khukhlaeva

et al. 2024

Burdenko's Journal of Neurosurgery

View full text Add to dashboard Cite

Synchronized Glioma Insights: Trends, Blood Group Correlations, Staging Dynamics, and the Vanguard of Liquid Biopsy Advancements

Sheikh,

Naqvi,

Al-Sulami

et al. 2025

CNSNDDT

View full text Add to dashboard Cite

Background: Gliomas are the most frequent, heterogeneous group of tumors arising from glial cells, characterized by difficult monitoring, poor prognosis, and fatality. Tissue biopsy is an established procedure for tumor cell sampling that aids diagnosis, tumor grading, and prediction of prognosis. Materials and Methods: We studied and compared the levels of liquid biopsy markers in patients with different grades of glioma. Also, we tried to prove the potential association between glioma and specific blood group antigens. Results: 78 patients were found, among whom the maximum percentage with glioblastoma had blood group O+ (53.8%). The second highest frequency had blood group A+ (20.4%), followed by B+ (9.0%) and A- (5.1%), and the least with O-. Liquid biopsy biomarkers included Alanine Aminotransferase (ALT), Lactate Dehydrogenase (LDH), lymphocytes, Urea, Alkaline phosphatase (AST), Neutrophils, and C-Reactive Protein (CRP). The levels of all the components increased significantly with the severity of the glioma, with maximum levels seen in glioblastoma (grade IV), followed by grade III and grade II, respectively. Conclusion: Gliomas have significant clinical challenges due to their progression with heterogeneous nature and aggressive behavior. A liquid biopsy is a non-invasive approach that aids in setting up the status of the patient and figuring out the tumor grade; therefore, it may show diagnostic and prognostic utility. Additionally, our study provides evidence to prove the role of ABO blood group antigens in the development of glioma. However, future clinical research on liquid biopsy will improve the sensitivity and specificity of these tests and confirm their clinical usefulness to guide treatment approaches.

show abstract

Molecular Biomarkers and Recent Liquid Biopsy Testing Progress: A Review of the Application of Biosensors for the Diagnosis of Gliomas

Cited by 4 publications

References 110 publications

Biosensors and disease diagnostics in medical field

Biosensors and disease diagnostics in medical field

Liquid biopsy in diagnosis of central nervous system tumors

Synchronized Glioma Insights: Trends, Blood Group Correlations, Staging Dynamics, and the Vanguard of Liquid Biopsy Advancements

Contact Info

Product

Resources

About